Lebrikizumab monotherapy improves quality of life (QoL) and mental health for patients with moderate-to-severe atopic dermatitis (AD), according to new data from ADvocate1 and ADvocate2 in Dermatology and Therapy.
Lebrikizumab is a targeted interleukin (IL)-13 inhibitor under investigation in the U.S with a decision from the Food and Drug Administration (FDA) expected in the second half of 2024.
In the studies, lebrikizumab-treated patients reported improvements in Dermatology Life Quality Index (DLQI) as early as Week 4, the first measure since baseline. These patients also reported significant improvements in all three measures of the EuroQoL 5-Dimension 5-Level (EQ-5D-5L), including the UK Health State Index, the US Health State Index, and visual analogue scale after 16 weeks.
.
“This is particularly relevant since approximately 30% of patients with AD report symptoms of anxiety or depression, [and] patients with moderate-to-severe AD in this study reported a very large impact on QoL at baseline (mean DLQI > 15),” conclude researchers led by Peter Lio, MD, a Clinical Assistant Professor of Dermatology and Pediatrics at Northwestern University Feinberg School of Medicine and a partner at Medical Dermatology Associates of Chicago in Chicago, IL.
Lilly has exclusive rights for the development and commercialization of lebrikizumab in Canada, the U.S., and the rest of the world outside Europe. Lilly’s partner Almirall S.A. has licensed the rights to develop and commercialize lebrikizumab for the treatment of dermatology indications in Europe.
Health Canada has granted Eli Lilly’s lebrikizumab (Ebglyss) authorization for moderate to severe atopic dermatitis (AD) in adults and adolescents aged 12 years and older. The European Commission approved lebrikizumab for the treatment of moderate to severe AD in adult and adolescent patients 12 years and older, and Germany was first country where lebrikizumab was available for prescription. Lebrikizumab is also approved in the United Kingdom and Japan.
